BR112012013710A2 - processos para a preparação de deferasirox e polimorfos de deferasirox. - Google Patents

processos para a preparação de deferasirox e polimorfos de deferasirox.

Info

Publication number
BR112012013710A2
BR112012013710A2 BR112012013710A BR112012013710A BR112012013710A2 BR 112012013710 A2 BR112012013710 A2 BR 112012013710A2 BR 112012013710 A BR112012013710 A BR 112012013710A BR 112012013710 A BR112012013710 A BR 112012013710A BR 112012013710 A2 BR112012013710 A2 BR 112012013710A2
Authority
BR
Brazil
Prior art keywords
deferasirox
processes
preparation
polymorphs
present
Prior art date
Application number
BR112012013710A
Other languages
English (en)
Inventor
Ehud Marom
Michael Mizhiritskii
Shai Rubnov
Original Assignee
Mapi Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mapi Pharma Ltd filed Critical Mapi Pharma Ltd
Publication of BR112012013710A2 publication Critical patent/BR112012013710A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
    • C07D291/02—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms not condensed with other rings
    • C07D291/06—Six-membered rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicinal Preparation (AREA)

Abstract

processos para a preparação de deferasirox e polimorfos de deferasirox. a presente invenção refere-se aos processos de preparação de deferasirox, um quelante de ferro oral desenvolvido para tratar a sobrecarga de ferro devido a, por exemplo, diversas transfusões de sangue. a presente invenção provê adicionalmente novos pseudopolimorfos de deferasirox e uma nova forma amorfa de deferasirox, processos para a sua preparação, bem como composições farmacêuticas compreendendo os mesmos, e uso dos mesmos em tratamento de sobrecarga de ferro.
BR112012013710A 2009-12-07 2010-01-28 processos para a preparação de deferasirox e polimorfos de deferasirox. BR112012013710A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26709609P 2009-12-07 2009-12-07
PCT/IL2010/000074 WO2011070560A1 (en) 2009-12-07 2010-01-28 Processes for the preparation of deferasirox, and deferasirox polymorphs

Publications (1)

Publication Number Publication Date
BR112012013710A2 true BR112012013710A2 (pt) 2015-09-15

Family

ID=44145166

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012013710A BR112012013710A2 (pt) 2009-12-07 2010-01-28 processos para a preparação de deferasirox e polimorfos de deferasirox.

Country Status (9)

Country Link
US (1) US8772503B2 (pt)
EP (1) EP2509423B1 (pt)
JP (1) JP2013512893A (pt)
CN (1) CN102638985A (pt)
AU (1) AU2010329487A1 (pt)
BR (1) BR112012013710A2 (pt)
CA (1) CA2781821A1 (pt)
MX (1) MX2012006434A (pt)
WO (1) WO2011070560A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2903712C (en) * 2013-03-06 2022-06-14 Biocon Limited Process for the preparation of deferasirox
WO2014136062A2 (en) * 2013-03-06 2014-09-12 Biocon Limited Process for the preparation of deferasirox
CN104098519B (zh) * 2013-04-08 2018-08-21 江苏豪森药业集团有限公司 地拉罗司的精制方法
CN103396373B (zh) * 2013-07-22 2015-02-04 江苏奥赛康药业股份有限公司 地拉罗司的制备方法及其中间体化合物
CN103554040B (zh) * 2013-11-08 2015-12-02 南京靖龙药物研发有限公司 一种地拉罗司衍生物的制备方法
CN104817538A (zh) * 2015-03-13 2015-08-05 东南大学 去铁斯诺-他克林金属离子鳌合剂及其药物用途
AU2016280280B2 (en) * 2015-06-17 2021-09-02 AustinPx, LLC Improved formulations of deferasirox and methods of making the same
WO2017019581A1 (en) * 2015-07-29 2017-02-02 Merck Sharp & Dohme Corp. Process for making phosphorus-containing nucleoside prodrug compounds
CN108456148B (zh) * 2018-05-09 2020-09-25 陕西理工大学 N-(3,4,5-三羟基苯甲酰)-3,4,5-三羟基苯甲酰胺及其制备方法与应用
CN112480073B (zh) * 2020-12-02 2022-03-22 武汉药明康德新药开发有限公司 1-烷基-3,5-芳基取代的1,2,4三氮唑化合物的合成方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2123897A5 (pt) 1971-02-04 1972-09-15 Rhone Poulenc Sa
US5175315A (en) 1989-05-31 1992-12-29 Florida State University Method for preparation of taxol using β-lactam
MY110249A (en) 1989-05-31 1998-03-31 Univ Florida State Method for preparation of taxol using beta lactam
TW226993B (pt) 1992-05-29 1994-07-21 Kumiai Chemical Industry Co
TW533205B (en) * 1996-06-25 2003-05-21 Novartis Ag Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition
GB0126618D0 (en) 2001-11-06 2002-01-02 Novartis Ag Organic compounds
WO2008065123A2 (en) 2006-11-29 2008-06-05 Novartis Ag Polymorphic forms of deferasirox ( icl670a)
WO2008094617A2 (en) * 2007-01-29 2008-08-07 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Crystalline forms of deferasirox
WO2009016359A1 (en) 2007-07-27 2009-02-05 Pliva Hrvatska D.O.O. New forms of deferasirox

Also Published As

Publication number Publication date
EP2509423B1 (en) 2016-01-27
US8772503B2 (en) 2014-07-08
US20120245361A1 (en) 2012-09-27
EP2509423A1 (en) 2012-10-17
CA2781821A1 (en) 2011-06-16
AU2010329487A1 (en) 2012-06-14
MX2012006434A (es) 2012-07-30
WO2011070560A1 (en) 2011-06-16
JP2013512893A (ja) 2013-04-18
CN102638985A (zh) 2012-08-15
EP2509423A4 (en) 2013-07-31

Similar Documents

Publication Publication Date Title
BR112012013710A2 (pt) processos para a preparação de deferasirox e polimorfos de deferasirox.
IL284530A (en) RNAI factors, compositions and methods of using them for the treatment of transthyretin-related diseases
BR112012009214A2 (pt) compostos
BR112012027509A2 (pt) composto, processo para a preparação de composto, composição farmacêutica, uso de composto, e, método
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
MX343620B (es) Forma polimorfica de clorhidrato de pridopidina.
IN2012DN02805A (pt)
PH12015500713B1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
GB201118656D0 (en) New compounds
EA201491028A1 (ru) Способ получения замещенных 5-фтор-1н-пиразолопиридинов
MY183588A (en) New salvianolic acid compound l, preparation method and use thereof
BR112014010183B8 (pt) Composto, composição farmacêutica, produto, e, uso de um composto
BR112013006857A2 (pt) composição farmacêutica, processo para preparar uma composição farmacêutica, uso de uma composição farmacêutica e método para o tratamento ou profilaxia de doenças virais
BR112015010196A2 (pt) métodos de tratar doença do fígado
BR112016007031A2 (pt) composição farmacêutica oral sólida, processo para a preparação de uma composição farmacêutica, composição farmacêutica bicamada oral sólida, e uso de uma composição farmacêutica
BR112015005560A2 (pt) derivados de macrolídeos, sua preparação e seu uso terapêutico
MX351994B (es) Formas cristalinas de [(s)-1-carbamoil-2-(feniil-pirimidin-2-il-am ino)-etil]-amida del acido 2-(2-metilamino-pirimidin-4-il)-1h-indo l-5-carboxilico.
IN2014DN10683A (pt)
MX2013002446A (es) Derivados de tetrahidropirrolopirazina sustituidos.
MX2013004650A (es) Polimorfos de febuxostat.
UA111139C2 (uk) Тверді фармацевтичні композиції і способи їхнього отримання

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]